Cell permeable, potent, selective and ATP-competitive inhibitor of TGF-β RI kinase (IC50=23nM, 4nM and 18nM for binding, auto-phosphorylation and cellular assay in HepG2 cells of TGF-β RI kinase, respectively). Minimally affects a panel of 9 closely related kinases including p38 MAPK (IC50>16µM).
Product Specification
| Alternative Name: | TGF-β RI Kinase Inhibitor II, 2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine |
| |
| Formula: | C17H13N5 |
| |
| MW: | 287.3 |
| |
| CAS: | 446859-33-2 |
| |
| Purity: | ≥97% (HPLC) |
| |
| Identity: | Determined by NMR. |
| |
| Appearance: | White to off-white or yellow solid. |
| |
| Solubility: | 5mg/ml soluble in DMSO or methanol. |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for 2 years after receipt when stored at -20°C. Stock solutions are stable for up to 6 months when stored at -20°C. |
| |
| Handling: | Protect from light. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
A hydrogel platform for in vitro three dimensional assembly of human stem cell-derived islet cells and endothelial cells: P. Augsornworawat, et al.; Acta Biomater.
97, 272 (2019),
Abstract;
Glucose-Responsiveness of Pancreatic β-Like (GRP β-L) Cells Generated from Human Pluripotent Stem Cells: B. Rajaei, et al.; Curr. Protoc. Hum. Genet.
100, e71 (2019),
Abstract;
Point mutations in the PDX1 transactivation domain impair human β-cell development and function: X. Wang, et al.; Mol. Metab.
24, 80 (2019),
Abstract;
Full Text
Generation and selection of pluripotent stem cells for robust differentiation to insulin-secreting cells capable of reversing diabetes in rodents: S.M. Southard, et al.; PLoS One
9, e0203126 (2018),
Abstract;
Full Text
Intrinsic Immunity Shapes Viral Resistance of Stem Cells: X. Wu, et al.; Cell
3, 423 (2018),
Abstract;
Full Text
Modeling signaling-dependent pluripotency with Boolean logic to predict cell fate transitions: A. Yachie-Kinoshita, et al.; Mol. Syst. Biol.
14, e7952 (2018),
Abstract;
Full Text
Cultured circulating tumor cells and their derived xenografts for personalized oncology: R. Wang, et al.; Asian J. Urol.
4, 240 (2016),
Abstract;
Full Text
Economic 3D-printing approach for transplantation of human stem cell-derived β-like cells: J. Song, et al.; Biofabrication
9, 015002 (2016),
Abstract;
ERRγ Is required for the metabolic maturation of therapeutically functional glucose-responsive β cells: E. Yoshihara, et al.; Cell Metab.
23, 622 (2016),
Abstract;
Full Text
Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mic: A.J. Vegas, et al.; Nat. Med.
22, 306 (2016),
Abstract;
Full Text
Emdogain-regulated gene expression in palatal fibroblasts requires TGF-βRI kinase signaling: A. Stähli, et al.; PLoS One
9, e105672 (2014),
Abstract;
Full Text
Generation of functional human pancreatic β cells in vitro: F.W. Pagliuca, et al.; Cell
159, 428 (2014),
Abstract;
Full Text
Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells: A. Rezania, et al.; Nat. Biotechnol.
32, 1121 (2014),
Application(s): Treatment of human iPSC-derived pancreatic endocrine precursors,
Abstract;
Inhibitors of Src and focal adhesion kinase promote endocrine specification: impact on the derivation of β-cells from human pluripotent stem cells: I. Afrikanova, et al.; J. Biol. Chem.
286, 36042 (2011),
Abstract;
Full Text
A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog: J.K. Ichida, et al.; Cell Stem Cell
5, 491 (2009),
Abstract;
Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors: F. Gellibert, et al.; J. Med. Chem.
47, 4494 (2004),
Abstract;
